ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi To Build Its First Antibody Plant

by Michael McCoy
May 11, 2009 | APPEARED IN VOLUME 87, ISSUE 19

Sanofi-Aventis is investing more than $250 million in Vitry-sur-Seine, France, to build its first monoclonal antibody production facility. The company says the production capacity will support its push into antibody-based drugs that complement its existing biotechnology-derived vaccines, insulin, and heparin. "Monoclonal antibodies will open the way to a new generation of better targeted and more effective treatments with fewer side effects," CEO Christopher A. Viehbacher said at an event last week to launch the construction project, which is expected to be completed by 2012. The Vitry-sur-Seine site will also house biotech R&D operations and be open to small drugmakers with which the French drug giant might collaborate. Sanofi will end pharmaceutical chemical activities at the site by 2011 and move production to other locations. The company recently announced a plan to prune 14 drug candidates from its development pipeline.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment